Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension: the RESTART Study
Objectives: * To assess the short-term and long-term changes in ambulatory and office blood pressure (BP) following native kidney RDN in renal transplant patients * To assess the long-term safety of native kidney RDN in renal transplant patients * To assess the short-term and long-term change in antihypertensive drug prescriptions following native kidney RDN in renal transplant patients * To assess the short-term and long-term change in adherence to antihypertensive drugs following native kidney RDN in renal transplant patients
• Age ≥ 18 years
• Kidney transplantation ≥ 12 months ago with stable immunosuppressive drug treatment
• Estimated Glomerular Filtration Rate (eGFR) ≥ 40 ml/min/1.73m2
• Office systolic BP ≥ 140 mmHg and a mean 24-hour ambulatory systolic BP ≥ 130 mmHg at screening
• Antihypertensive medication regimen:
‣ Stable regimen of at least two antihypertensive drugs of different classes, including a diuretic (defined a thiazide diuretic, loop diuretic or mineralocorticoid receptor antagonist), for at least three months, or
⁃ Documented intolerance to three classes of antihypertensive drugs, and
⁃ A change in antihypertensive drug regimen is not anticipated within the oncoming three months.
• Patient is willing and able to provide written informed consent